InvestorsHub Logo
Post# of 251670
Next 10
Followers 827
Posts 119535
Boards Moderated 15
Alias Born 09/05/2002

Re: DewDiligence post# 241772

Wednesday, 03/23/2022 5:22:46 PM

Wednesday, March 23, 2022 5:22:46 PM

Post# of 251670
NVS’ 2017 entry into radioligand field:

https://www.reuters.com/article/us-novartis-advanced-accelerator/novartis-to-buy-french-cancer-specialist-aaa-for-3-9-billion-idUSKBN1CZ0HC

NVS acquired AAAP in Oct 2017, thereby gaining ownership of Lutathera, a radioligand for neuroendocrine tumors. NVS paid a 47% premium in an all-cash deal valued at $3.9B.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.